Alirocumab + statin therapy
Alirocumab + statin therapy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Oct 23, 2026: “Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery Disease”.
1 paper studies it4 findingsUpdated
1 new paper in 30 daysSee all 1 papers on alirocumab + statin therapy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“The reductions in total cholesterol, LDL-C, and ApoB were greater in the combination group than in the comparison group”
None of its findings points the other way.
- 1 lab in 1 country
- Humans1
What did studies of alirocumab + statin therapy find?
3Studies of alirocumab + statin therapy measured 3 outcomes: creatinine, flow-mediated dilation and LDL-C.
Creatinine
no changein humans1
1 study
Creatinine
no changein humans1
Alirocumab + statin therapy was not clearly linked with creatinine in humans (Coronary artery disease after PCI; compared with the regimen without a PCSK9 inhibitor).
“between-group differences in changes in creatinine and CK were not statistically significant (P = 0.373 and P = 0.335, respectively).”
HumansCoronary artery disease after PCI; compared with the regimen without a PCSK9 inhibitor8 weeksn = 62
Research SquarePreprint
Flow-mediated dilation
upin humans1
1 study
Flow-mediated dilation
upin humans1
Alirocumab + statin therapy is linked with better flow-mediated dilation in humans (Vascular subgroup with coronary artery disease after PCI; compared with statin monotherapy).
“was associated with favorable changes in FMD and selected measures of arterial elasticity.”
HumansVascular subgroup with coronary artery disease after PCI; compared with statin monotherapybrachial artery8 weeksn = 22
Research SquarePreprint
LDL-C
downin humans1
1 study
LDL-C
downin humans1
Alirocumab + statin therapy is linked with lower LDL-C in humans (Coronary artery disease after PCI; compared with statin monotherapy).
“The reductions in total cholesterol, LDL-C, and ApoB were greater in the combination group than in the comparison group”
HumansCoronary artery disease after PCI; compared with statin monotherapy8 weeksn = 62
Research SquarePreprint
What is alirocumab + statin therapy linked with?
1Studies link alirocumab + statin therapy with ALT.
ALT
downin humans1
1 study
ALT
downin humans1
Alirocumab + statin therapy is associated with ALT in humans (Combination group with coronary artery disease after PCI; compared with baseline).
“ALT and AST decreased from baseline in the combination group (P = 0.030 and P = 0.002, respectively)”
HumansCombination group with coronary artery disease after PCI; compared with baseline8 weeksn = 22
Research SquarePreprint